Cancer Management & Treatment | Cancer Research & Drug Trials

Top News

Adult Survivors of Childhood Cancer May Face Late-Onset Memory Impairment

CVD Events Increased for Cancer Patients Who Continue Smoking After Diagnosis

Lynparza Combo Approved for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

Biomarker-Guided ICI Therapy Provides Greater Benefit in Cancer Patients

CIRS-G Reveals Accelerated Aging, Early Death in Childhood Cancer Survivors

Palliative Care Does Not Improve HRQOL in Context of Gastrointestinal Cancer Surgery

Taking Vitamin D₃ Supplements Daily May Reduce Risk of Cancer Death

Repotrectinib Gets Priority Review for ROS1-Positive NSCLC

US COVID-19 Hospitalizations Drop Below 9000, Potentially Due to Change in Testing

Switching ET and Adding Ribociclib Improves PFS in HR+, HER2- Breast Cancer

Targeted Adjuvant Therapies Provide No Survival Benefit in Stage III Melanoma

Lung Cancer Survival by Smoking Status and Other Risk Factors

EDITORIAL ADVISORY BOARD

Barbara Ann Burtness, MD

Steven Cohen, MD

E. David Crawford, MD

Don S. Dizon, MD, FACP

Jeffrey M. Farma, MD

Neal D. Shore, MD, FACS

Mark A. Socinski, MD

Mario Sznol, MD

Click here for complete profiles

Featured

Update on Bladder Cancer Risk Factors

A recent review provided an update on traditional and novel risk factors for bladder cancer that may help guide prevention efforts.
State of Cancer Research: Impact of COVID-19, Brexit, War, and Other Global Events

In the last few years, cancer research has been hindered by the COVID-19 pandemic, Brexit, the war in Ukraine, and tensions between world superpowers.
Global Survey Suggests RCC Patients Are Underinformed, Face Obstacles to Care

Results of a global survey highlight areas for improvement in the care of patients with renal cell carcinoma.
Lack of Access to Abortion Has Had a Negative Impact on Cancer Care

Since the US Supreme Court overturned Roe v Wade last year, restrictions on access to abortion have had a negative impact on cancer care.
Ibrutinib No Longer Approved for MCL, MZL: How This Change Will Affect Patients

The withdrawn approvals of ibrutinib for relapsed/refractory MCL and MZL are likely to have a limited impact on patients, experts say.

More Features

Lung cancer

AACR 2023 Highlights Novel Research in NSCLC and ES-SCLC

By

Tori Rodriguez, MA, LPC, AHC

Could Shopping Data Be Used to Predict Cancer and Diagnose It Earlier?

By

Carina Storrs, PhD

Could mRNA Vaccines Help Prevent Recurrence in Pancreatic Cancer?

By

Alan P. Lyss, MD

ART and Pediatric Cancer: Risk May Vary by Method Used, Cancer Type

By

Carina Storrs, PhD

Cancer patient receiving chemotherapy

Characteristics, Treatment Options for Patients With Advanced Gynecologic Cancers

By

Joyce Pagan

More Features »

Fact Sheets

Vaccination

Fact Sheet: COVID-19 Vaccine Considerations for Patients With Cancer

COVID-19 testing

What to Expect: Enrolling on a Cancer Clinical Trial During COVID-19